TGF-β2 Reduces Demyelination, Virus Antigen Expression, and Macrophage Recruitment in a Viral Model of Multiple Sclerosis
Tóm tắt
TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler’s murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.
Từ khóa
Tài liệu tham khảo
Dal Canto, M. C., H. L. Lipton. 1975. Primary demyelination in Theiler’s virus infection: an ultrastructural study. Lab. Invest. 33: 626
Lipton, H. L.. 1975. Theiler’s virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect. Immun. 11: 1147
Lipton, H. L., M. C. Dal Canto. 1976. Theiler’s virus-induced demyelination: prevention by immunosuppression. Science 192: 62
Rodriguez, M., J. Quddus. 1986. Effect of cyclosporin A, silica quartz dust and protease inhibitors on virus-induced demyelination. J. Neuroimmunol. 13: 159
Rodriguez, M., S. Sriram. 1988. Successful therapy of TMEV-induced demyelination (DA strain) with monoclonal anti-Lyt2. 2 antibody. J. Immunol. 140: 2950
Rodriguez, M., K. D. Pavelko, R. L. Coffman. 1995. γ Interferon is critical for resistance to Theiler’s virus-induced demyelination. J. Virol. 69: 7286
Fiette, L., C. Aubert, U. Muller, S. Huang, M. Auget, M. Brahic, J. F. Bureau. 1995. Theiler’s virus infection of 129 Sv mice that lack the interferon α/β or interferon γ receptors. J. Exp. Med. 181: 2069
Bureau, J. F., X. Montagutelli, F. Bihl, S. Lefebvre, J. L. Guenet, M. Brahic. 1993. Mapping loci influencing the persistence of Theiler’s virus in the murine central nervous system. Nat. Genet. 5: 87
Rodriguez, M., K. D. Pavelko, C. W. McKinney, J. L. Leibowitz. 1994. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. 153: 3811
Paya, C. V., P. J. Leibson, A. K. Patick, M. Rodriguez. 1990. Inhibition of Theiler’s virus-induced demyelination in vivo by tumor necrosis factor α. Int. Immunol. 2: 909
Pullen, L. C., S. H. Park, S. D. Miller, M. C. Dal Canto, B. S. Kim. 1995. Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler’s virus-induced demyelinating disease. J. Immunol. 155: 4497
Larsson-Sciard, E. L., S. Dethlefs, M. Brahic. 1997. In vivo administration of interleukin-2 protects susceptible mice from Theiler’s virus persistence. J. Virol. 71: 797
Czarniecki, C. W., H. H. Chiu, G. H. W. Wong, S. M. McCabe, M. A. Palladino. 1988. Transforming growth factor β1 modulates the expression of class II histocompatibility complex antigens on human cells. J. Immunol. 140: 4217
Kuruvilla, A. P., R. Shah, G. M. Hochwald, H. D. Liggitt, M. A. Palladino, G. J. Thorbecke. 1991. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA 88: 2918
Racke, M. K., S. Dhib-Jalbut, B. Cannella, P. S. Albert, C. S. Raine, D. E. McFarlin. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146: 3012
Racke, M. K., S. Sriram, J. Carlino, B. Cannella, C. S. Raine, D. E. McFarlin. 1993. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2. J. Neuroimmunol. 46: 175
Rodriguez, M., J. L. Leibowitz, P. W. Lampert. 1983. Persistent infection of oligodendrocytes in Theiler’s virus-induced encephalomyelitis. Ann. Neurol. 13: 426
Pierce, M. L., M. Rodriguez. 1989. Erichrome stain for myelin on osmicated tissue embedded in glycol methacrylate plastic. J. Histotechnol. 12: 35
Drescher, K. M., L. T. Nguyen, V. Taneja, M. J. Coenen, J. L. Leibowitz, G. Strauss, G. J. Hammerling, C. S. David, M. Rodriguez. 1998. Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis. J. Clin. Invest. 101: 1765
Drescher, K. M., C. Rivera-Quinones, C. F. Lucchinetti, M. Rodriguez. 1998. Failure of linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. J. Neuroimmunol. 88: 111
Rodriguez, M., W. P. Lafuse, J. Leibowitz, C. S. David. 1986. Partial suppression of Theiler’s virus-induced demyelination in vivo by administration of monoclonal antibodies to immune-response gene products (Ia antigens). Neurology 36: 964
Leibowitz, J., M. Rodriguez. 1983. Antigenic variants are not selected during persistent infection with Theiler’s virus. Infect. Immun. 41: 440
Lin, X., R. Thiemann, L. R. Pease, M. Rodriguez. 1995. VP1 and VP2 capsid proteins of Theiler’s virus are targets of H-2D-restricted cytotoxic lymphocytes in the central nervous system of B10 mice. Virology 214: 91
Rodriguez, M., A. K. Patick, L. R. Pease. 1990. Abrogation of resistance to Theiler’s virus-induced demyelination in C57BL mice by total body irradiation. J. Neuroimmunol. 26: 189
Rodriguez, M., C. Nickerson, A. K. Patick, C. S. David. 1991. Expression of human HLA-B27 transgene alters susceptibility to murine Theiler’s virus-induced demyelination. J. Immunol. 146: 2596
Rodriguez, M., S. Pedrinaci, C. S. David. 1993. Human class I major histocompatibility complex transgene prevents virus-induced demyelination in susceptible mutant B10.D2dml mice. Ann. Neurol. 33: 208
Njenga, M. K., K. D. Pavelko, J. Baisch, X. Lin, C. David, J. Leibowitz, M. Rodriguez. 1996. Theiler’s virus persistence and demyelination in major histocompatibility complex class II-deficient mice. J. Virol. 70: 1729
Rodriguez, M., J. J. Kenny, R. L. Thiemann, G. E. Woloschak. 1990. Theiler’s virus-induced demyelination in mice immunosuppressed with anti-IgM and in mice expressing the xid gene. Microb. Pathog. 8: 23
Cash, E., A. Bandeira, S. Chirinian, M. Brahic. 1989. Characterization of B lymphocytes present in the demyelinating lesions induced by Theiler’s virus. J. Immunol. 143: 984
Kondo, S., K. Isobe, N. Ishiguro, I. Nakashima, T. Miura. 1993. Transforming growth factor-β1 enhances the generation of allospecific cytotoxic T lymphocytes. Immunology 79: 459
Lin, X., L. R. Pease, M. Rodriguez. 1997. Differential generation of class I H-2D-versus H-2K-restricted cytotoxicity against a demyelinating virus following central nervous system infection. Eur. J. Immunol. 27: 963
Pena Rossi, C., A. McAllister, L. Fiette, M. Brahic. 1991. Theiler’s virus infection induces a specific cytotoxic T lymphocyte response. Cell. Immunol. 138: 341
Lin, X., L. R. Pease, P. D. Murray, M. Rodriguez. 1998. Theiler’s virus infection of genetically susceptible mice induces central nervous system-infiltrating CTLs with no apparent viral or major myelin antigenic specificity. J. Immunol. 160: 5661
Xiao, B. G., X. F. Bai, G. X. Zhang, H. Link. 1997. Transforming growth factor-β1 induces apoptosis of rat microglia without relation to bcl-2 oncoprotein expression. Neurosci. Lett. 226: 71
Kim, E. S., R. S. Kim, R. F. Ren, D. B. Hawver, K. C. Flanders. 1998. Transforming growth factor-β inhibits apoptosis induced by β-amyloid peptide fragment 25-35 in cultured neuronal cells. Brain Res. 62: 122
Levy, M., C. Aubert, M. Brahic. 1992. Theiler’s virus replication in brain macrophages cultured in vitro. J. Virol. 66: 3188
Rossi, C. P., M. Delcroix, I. Huitinga, A. McAllister, N. Van Rooijen, E. Claassen, M. Brahic. 1997. Role of macrophages during Theiler’s virus infection. J. Virol. 71: 3336
Nelson, B. J., P. Ralph, S. J. Green, C. A. Nacy. 1991. Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-β1. J. Immunol. 146: 1849
Ding, A., C. F. Nathan, J. Graycar, R. Derynck, D. J. Stuehr, S. Sriram. 1990. Macrophages deactivating factor and transforming growth factor-β1, β2, and β3 inhibit induction of macrophage nitric oxide synthesis by IFN-γ. J. Immunol. 145: 940
Espevik, T., I. S. Figari, M. R. Shalaby, G. A. Lackides, G. D. Lewis, H. M. Shepard, M. A. Palladino. 1987. Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J. Exp. Med. 166: 571
Tsunawaki, S., M. B. Sporn, A. Ding, C. Nathan. 1988. Deactivation of macrophages by transforming growth factor-β. Nature 334: 260
Schluesener, H. L., O. Lider. 1989. Transforming growth factors β1 and β2: cytokines with identical immunosuppressive effects and a potential role in the immunoregulation of autoimmune T cell function. J. Neuroimmunol. 24: 249
Borson, N. D., C. Paul, X. Lin, W. K. Nevala, M. A. Strausbauch, M. Rodriguez, P. J. Wettstein. 1997. Brain-infiltrating CTLs specific for Theiler’s virus recognize H-2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue. J. Virol. 71: 5244
Murray, P. D., K. D. Pavelko, J. Leibowitz, X. Lin, M. Rodriguez. 1998. CD4+ and CD8+ T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. J. Virol. 72: 7320